ISPOR Announces 2017-2018 Board of Directors

Published Jun 6, 2017
Princeton, NJ—June 6, 2017—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced the election of the Society’s 2017-2018 Board of Directors. The new Board will assume office on July 1, 2017. The ISPOR Board of Directors are elected by its global membership. Shelby D. Reed, RPh, PhD assumes the role of president (2017-2018) after having served as the Society’s President-Elect. Dr. Reed is a professor at Duke University in Durham, NC, USA. Federico Augustovski, MD, MSc, PhD was elected to the position of president-elect (2017-2018). Dr. Augustovski is director of Health Economic Evaluations and Technology Assessment at the Institute for Clinical Effectiveness and Health Policy in Buenos Aires, Argentina. The following members were recently elected to the ISPOR Board of Directors for 3-year terms:
  • Meindert Boysen, PharmD, director for technology appraisal and highly-specialized technologies programs at the National Institute for Health and Care Excellence, London, England, UK
  • Stephanie R. Earnshaw, PhD, senior vice president, Health Economics at RTI Health Solutions, Raleigh-Durham, NC, USA
  • Jan Elias Hansen, PhD, vice president, Evidence for Access Unit, US Medical Affairs at Genentech, South San Francisco, CA, USA
Returning Board members include: Immediate Past President:
  • Lou Garrison, PhD, professor emeritus, Pharmaceutical Outcomes Research and Policy Program in the School of Pharmacy and adjunct professor, Departments of Global Health and Health Services at the University of Washington, Seattle, WA, USA
Treasurer:
  • Zeba M. Khan, RPh, PhD, vice president at Celgene Corporation, Summit, NJ, USA—reappointed to a second three-year term
CEO and Executive Director:
  • Nancy S. Berg, CEO and executive director at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ, USA
Returning Board Members:
  • Joanna Lis, MSc, MBAPhD,director, Market Access at Sanofi-Aventis, Warsaw, Poland
  • Gordon Liu, PhD, PKU Yangtze River Scholar professor of economics at Peking University National School of Development and director at PKU China Center for Health Economic Research, Beijing, China
  • Rosanna Tarricone, MScPhD,associate professor at Bocconi University, Milan, Italy
  • John Watkins, MPHPharmD, formulary manager at Premera Blue Cross, Mountlake Terrace, WA, USA

###

  ABOUT ISPOR The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that promotes health economics and outcomes research excellence to improve decision making for health globally. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT | Facebook: http://bit.ly/ISPOR-FB  

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×